In an attempt to diversify its pipeline, Biogen has agreed to acquire Human Immunology Biosciences (HI-Bio) for US$1.15 B upfront and up to US$650 M in potential milestone payments. Through the takeover, Biogen gains rights HI-Bio’s lead asset felzartamab, an investigational anti-CD38 monoclonal antibody with promise as a pipeline-in-a-product across a range of immune-mediated diseases. After a turbulent few months for the company, the deal marks yet another move by Biogen to diversify its portfolio beyond neuroscience and secure potential future revenue generators.